Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2

Faísca et al., Pharmaceutics, doi:10.3390/pharmaceutics14040877
Apr 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19hcq.org
In Vitro study showing improved antiviral activity with ionic formulations of HCQ.
34 preclinical studies support the efficacy of HCQ for COVID-19:
5 studies investigate novel formulations of HCQ for improved efficacy12,18,32-34
Faísca et al., 17 Apr 2022, peer-reviewed, 6 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperHCQAll
Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2
Francisco Faísca, Vanessa Correia, Željko Petrovski, Luís C Branco, Helena Rebelo-De-Andrade, Miguel M Santos
Pharmaceutics, doi:10.3390/pharmaceutics14040877
The development of effective antiviral drugs against SARS-CoV-2 is urgently needed and a global health priority. In light of the initial data regarding the repurposing of hydroxychloroquine (HCQ) to tackle this coronavirus, herein we present a quantitative synthesis and spectroscopic and thermal characterization of seven HCQ room temperature ionic liquids (HCQ-ILs) obtained by direct protonation of the base with two equivalents of organic sulfonic, sulfuric and carboxylic acids of different polarities. Two non-toxic and hydrophilic HCQ-ILs, in particular, [HCQH 2 ][C 1 SO 3 ] 2 and [HCQH 2 ][GlcCOO] 2 , decreased the virus-induced cytopathic effect by two-fold in comparison with the original drug, [HCQH 2 ][SO 4 ]. Despite there being no significant differences in viral RNA production between the three compounds, progeny virus production was significantly affected (p < 0.05) by [HCQH 2 ][GlcCOO] 2 . Overall, the data suggest that the in vitro antiviral activities of the HCQ-ILs are most likely the result of specific intra-and intermolecular interactions and not so much related with their hydrophilic or lipophilic character. This work paves the way for the development of future novel ionic formulations of hydroxychloroquine with enhanced physicochemical properties.
(9) resulted in more than 60% inhibition of CPE at 10 µ M (70.5%, 60.8% and 62.5%, respectively), which contrasted with the remaining compounds, including 1 (lower than 20%; see Figure 3A ). The EC50 values of these three novel formulations (8.1, 8.9 and 8.5 µ M, respectively) were significantly lower than those of all other HCQ-ILs and differed by ca. two-fold from the EC50 of 1 (16.5 µ M) (Table 5 ). No significant differences in EC90 were observed between the seven novel HCQ-ILs and 1, with all values being registered beyond 20 µM. Table 5 . The 50% (EC50) and 90% (EC90) effective concentrations of [HCQH2][SO4] (1) and HCQ-ILs 3-9 for the inhibition of the virus-induced cytopathic effect (CPE) on Vero E6 cells infected with SARS-CoV-2. The results are presented as the mean of three independent experiments with triplicate measurements. The 95% confidence interval (CI) is indicated in a separate column. SI represents the CC50/EC50 selectivity ratio. No inhibitory effects were found for the anions. Significant differences (SIG diff.) were evaluated using a one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test. A p-value < 0.05 was considered significant, with * p < 0.05, ** p < 0.01, *** p < 0.001. The enhanced antiviral activity of 3 and 9 in this initial screening doubled their SI ratio (26.9 and 23.1, respectively) in comparison with 1 (13.0) (Table 5 ), leading them to be identified as the most promising HCQ-ILs. Hence, these..
References
Al-Sabagh, Azzam, Mahmoud, Saleh, Synthesis of Ethoxylated Alkyl Sulfosuccinate Surfactants and the Investigation of Mixed Solutions, J. Surfactants Deterg, doi:10.1007/s11743-006-1000-8
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the Treatment of Covid-19-Final Report, N. Engl. J. Med, doi:10.1056/NEJMoa2007764
Ben-Zvi, Kivity, Langevitz, Shoenfeld, Hydroxychloroquine: From Malaria to Autoimmunity, Clin. Rev. Allergy Immunol, doi:10.1007/s12016-010-8243-x
Billington, Reid, Benefits of Bisphosphonate Therapy: Beyond the Skeleton, Curr. Osteoporos. Rep
Burki, The Role of Antiviral Treatment in the COVID-19 Pandemic, Lancet Respir. Med, doi:10.1016/S2213-2600(22)00011-X
Carrera, Santos, Costa, Rebelo, Marrucho et al., Highly Water Soluble Room Temperature Superionic Liquids of APIs, New J. Chem, doi:10.1039/C7NJ01398A
Childs, Chyall, Dunlap, Smolenskaya, Stahly et al., Crystal Engineering Approach to Forming Cocrystals of Amine Hydrochlorides with Organic Acids. Molecular Complexes of Fluoxetine Hydrochloride with Benzoic, Succinic, and Fumaric Acids, J. Am. Chem. Soc, doi:10.1021/ja048114o
Cole, Li, El-Zahab, Janes, Hayes et al., Synthesis, and Biological Evaluation of β-Lactam Antibiotic-Based Imidazolium-and Pyridinium-Type Ionic Liquids, Chem. Biol. Drug Des, doi:10.1111/j.1747-0285.2011.01114.x
Dean, Turanjanin, Yoshizawa-Fujita, Macfarlane, Scott, Exploring an Anti-Crystal Engineering Approach to the Preparation of Pharmaceutically Active Ionic Liquids, Cryst. Growth Des, doi:10.1021/cg8009496
Egorova, Gordeev, Ananikov, Biological Activity of Ionic Liquids and Their Application in Pharmaceutics and Medicine, Chem. Rev, doi:10.1021/acs.chemrev.6b00562
El Keshky, Basyouni, Al Sabban, Corrigendum: Getting through COVID-19: The Pandemic's Impact on the Psychology of Sustainability, Quality of Life, and the Global Economy-A Systematic Review, Front. Psychol, doi:10.3389/fpsyg.2021.700815
Elder, Holm, De Diego, Use of Pharmaceutical Salts and Cocrystals to Address the Issue of Poor Solubility, Int. J. Pharm, doi:10.1016/j.ijpharm.2012.11.028
Eng, Chew, Jin, Chua, In Vitro Inhibition of Human Influenza A Virus Replication by Chloroquine, Virol. J, doi:10.1186/1743-422X-3-39
Fan, Zhang, Liu, Yang, Zheng et al., Connecting Hydroxychloroquine in Vitro Antiviral Activity to in Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients with Coronavirus Disease, Clin. Infect. Dis, doi:10.1093/cid/ciaa623
Fanouriakis, Kostopoulou, Alunno, Aringer, Bajema et al., Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus, Ann. Rheum. Dis, doi:10.1136/annrheumdis-2019-215089
Ferraz, Silva, Dias, Dias, Santos et al., Synthesis and Antibacterial Activity of Ionic Liquids and Organic Salts Based on Penicillin g and Amoxicillin Hydrolysate Derivatives against Resistant Bacteria, Pharmaceutics, doi:10.3390/pharmaceutics12030221
Ferraz, Teixeira, Rodrigues, Fernandes, Prudêncio et al., Antibacterial Activity of Ionic Liquids Based on Ampicillin against Resistant Bacteria, RSC Adv, doi:10.1039/C3RA44286A
Flannery, Chatterjee, Winzeler, Antimalarial Drug Discovery-Approaches and Progress towards New Medicines, Nat. Rev. Microbiol, doi:10.1038/nrmicro3138
Florindo, Costa, Matos, Nunes, Matias et al., Novel Organic Salts Based on Fluoroquinolone Drugs: Synthesis, Bioavailability and Toxicological Profiles, Int. J. Pharm, doi:10.1016/j.ijpharm.2014.04.034
Gard, Ennis, Summerfield, 1-Octanol/Water Partition Coefficients of Dialkylated Methylimidazolium Halide Salts, Glob. J. Sci. Front. Res. B Chem
Gbinigie, Fri, Should Chloroquine and Hydroxychloroquine Be Used to Treat COVID-19? A Rapid Review, BJGP Open, doi:10.3399/bjgpopen20X101069
Gindri, Siddiqui, Bhardwaj, Rodriguez, Palmer et al., Dicationic Imidazolium-Based Ionic Liquids: A New Strategy for Non-Toxic and Antimicrobial Materials, RSC Adv
Gordon, Amissah-Arthur, Gayed, Brown, Bruce et al., The British Society for Rheumatology Guideline for the Management of Systemic Lupus Erythematosus in Adults, Rheumatology, doi:10.1093/rheumatology/kex286
Guglielmero, Mezzetta, Guazzelli, Pomelli, ; D'andrea et al., Systematic Synthesis and Properties Evaluation of Dicationic Ionic Liquids, and a Glance into a Potential New Field, Front. Chem, doi:10.3389/fchem.2018.00612
Hoffmann, Kleine-Weber, Schroeder, Krüger, Herrler et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, doi:10.1016/j.cell.2020.02.052
Hough, Smiglak, Rodríguez, Swatloski, Spear et al., The Third Evolution of Ionic Liquids: Active Pharmaceutical Ingredients, New J. Chem, doi:10.1039/b706677p
Huttunen, Raunio, Rautio, Prodrugs-from Serendipity to Rational Design, Pharmacol. Rev
Hz, -G, -f, H-j) ppm. 13 C NMR (126 MHz
Hz, -G, -f, H-j) ppm. 13 C NMR (126 MHz
Hz, 6H, H-f) ppm. 13 C NMR (126 MHz
Hz, 6H, H-f) ppm. 13 C NMR (126 MHz
Hz, 6H, H-f) ppm. 13 C NMR (126 MHz
Hz, H-e, H-g
Hz, None
Hz, None
Hz, None
Hz, None, 2H, H-b
Hz, None, 2H, H-b″
Hz, None, 2H, H-b″
Hz, None, H
Hz, None, H
Hz, None, H
Hz, None, H
Hz, None, H
Hz, None, H
Hz, None, H
Hz, None, H
Hz, None, H
Hz, None, H-21
Hz, None, H-21
Hz, None, H-21
Hz, None, J =
Hz, None, J =
Hz, None, J =
Hz, None, J = 6
Hz, None, J = 6
Hz, None, J = 6
Keyaerts, Li, Vijgen, Rysman, Verbeeck et al., Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice, Antimicrob. Agents Chemother, doi:10.1128/AAC.01509-08
Keyaerts, Vijgen, Maes, Neyts, Van Ranst, In Vitro Inhibition of Severe Acute Respiratory Syndrome Coronavirus by Chloroquine, Biochem. Biophys. Res. Commun, doi:10.1016/j.bbrc.2004.08.085
Leuner, Dressman, Improving Drug Solubility for Oral Delivery Using Solid Dispersions, Eur. J. Pharm. Biopharm, doi:10.1016/S0939-6411(00)00076-X
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a Less Toxic Derivative of Chloroquine, Is Effective in Inhibiting SARS-CoV-2 Infection In Vitro, Cell Discov, doi:10.1038/s41421-020-0156-0
Lu, Zhao, Li, Niu, Yang et al., Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding, Lancet
Madeira, Alves, Silva, Florindo, Costa et al., Fluoroquinolone-Based Organic Salts and Ionic Liquids as Highly Bioavailable Broad-Spectrum Antimicrobials, Proceedings, doi:10.3390/iecp2020-08649
Mero, Mezzetta, Nowicki, Łuczak, Guazzelli, Betaine and L-Carnitine Ester Bromides: Synthesis and Comparative Study of Their Thermal Behaviour and Surface Activity, J. Mol. Liq, doi:10.1016/j.molliq.2021.115988
Mezzetta, Perillo, Guazzelli, Chiappe, Thermal Behavior Analysis as a Valuable Tool for Comparing Ionic Liquids of Different Classes, J. Therm. Anal. Calorim, doi:10.1007/s10973-019-08951-w
Murgolo, Therien, Howell, Klein, Koeplinger et al., SARS-CoV-2 Tropism, Entry, Replication, and Propagation: Considerations for Drug Discovery and Development, PLoS Pathog, doi:10.1371/journal.ppat.1009225
Nmr, 6 ) δ 171, DMSO-d
Nmr, 6 ) δ 8.71, DMSO-d
Nmr, d 6 ) δ 8.60, J = 9.1 Hz, 1H, H-15
Nmr, d6) δ 8.60, DMSO
Nmr, d6) δ 8.60, DMSO
Nmr, δ 8.71, DMSO-d6)
Nmr, δ 8.71, DMSO-d6)
Ohkuma, Poole, Fluorescence Probe Measurement of the Intralysosomal PH in Living Cells and the Perturbation of PH by Various Agents, Proc. Natl. Acad. Sci, doi:10.1073/pnas.75.7.3327
Pan, Peto, Henao-Restrepo, Preziosi, Sathiyamoorthy et al., Repurposed Antiviral Drugs for COVID-19-Interim WHO Solidarity Trial Results, N. Engl. J. Med
Patil, Talebi, Xu, Bhawal, Armstrong, Synthesis of Thermally Stable Geminal Dicationic Ionic Liquids and Related Ionic Compounds: An Examination of Physicochemical Properties by Structural Modification, Chem. Mater, doi:10.1021/acs.chemmater.6b01247
Paton, Aboulhab, Hydroxychloroquine, Hydroxyurea and Didanosine as Initial Therapy for HIV-Infected Patients with Low Viral Load: Safety, Efficacy and Resistance Profile after 144 Weeks, HIV Med, doi:10.1111/j.1468-1293.2005.00259.x
Pedro, Freire, Silvestre, Freire, The Role of Ionic Liquids in the Pharmaceutical Field: An Overview of Relevant Applications, Int. J. Mol. Sci, doi:10.3390/ijms21218298
Pons-Estel, Bonfa, Soriano, Cardiel, Izcovich et al., First Latin American Clinical Practice Guidelines for the Treatment of Systemic Lupus Erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio Del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR), Ann. Rheum. Dis, doi:10.1136/annrheumdis-2018-213512
Ratajczak, Orville-Thomas, Molecular Interactions
Reed, Muench, A Simple Method of Estimating Fifty per Cent Endpoints, Am. J. Epidemiol, doi:10.1093/oxfordjournals.aje.a118408
Ridley, Medical Need, Scientific Opportunity and the Drive for Antimalarial Drugs, Nature, doi:10.1038/415686a
Santos, Alves, Silva, Florindo, Costa et al., Antimicrobial Activities of Highly Bioavailable Organic Salts and Ionic Liquids from Fluoroquinolones, Pharmaceutics, doi:10.3390/pharmaceutics12080694
Santos, Branco, Duarte, Organic Salts Based on Isoniazid Drug: Synthesis, Bioavailability and Cytotoxicity Studies, Pharmaceutics, doi:10.3390/pharmaceutics12100952
Santos, Raposo, Carrera, Costa, Dionísio et al., Ionic Liquids and Salts from Ibuprofen as Promising Innovative Formulations of an Old Drug, ChemMedChem, doi:10.1002/cmdc.201900040
Schilling, White, Does Hydroxychloroquine Still Have Any Role in the COVID-19 Pandemic? Expert, Opin. Pharmacother, doi:10.1080/14656566.2021.1898589
Serajuddin, Salt Formation to Improve Drug Solubility, Adv. Drug Deliv. Rev, doi:10.1016/j.addr.2007.05.010
Shibata, Aoki, Tsurumi, Sugiura, Nishiyama et al., Mechanism of Uncoating of Influenza B Virus in MDCK Cells: Action of Chloroquine, J. Gen. Virol, doi:10.1099/0022-1317-64-5-1149
Shukla, Archibald, Shukla, Mehta, Cherabuddi, Chloroquine and Hydroxychloroquine in the Context of COVID-19, Drugs Context, doi:10.7573/dic.2020-4-5
Skittrall, Wilson, Smielewska, Parmar, Fortune et al., Specificity and Positive Predictive Value of SARS-CoV-2 Nucleic Acid Amplification Testing in a Low-Prevalence Setting, Clin. Microbiol. Infect, doi:10.1016/j.cmi.2020.10.003
Smolen, Landewé, Bijlsma, Burmester, Dougados et al., EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2019 Update, Ann. Rheum. Dis, doi:10.1136/annrheumdis-2019-216655
Stella, Prodrugs: Some Thoughts and Current Issues, J. Pharm. Sci, doi:10.1002/jps.22205
Tampucci, Guazzelli, Burgalassi, Carpi, Chetoni et al., PH-Responsive Nanostructures Based on Surface Active Fatty Acid-Protic Ionic Liquids for Imiquimod Delivery in Skin Cancer Topical Therapy, Pharmaceutics, doi:10.3390/pharmaceutics12111078
Tao, Tzou, Nouhin, Bonilla, Jagannathan et al., SARS-CoV-2 Antiviral Therapy, Clin. Microbiol. Rev, doi:10.1128/CMR.00109-21
Teixeira, Santos, Branco, Costa-Rodrigues, Etidronate-Based Organic Salts and Ionic Liquids: In Vitro Effects on Bone Metabolism, Int. J. Pharm, doi:10.1016/j.ijpharm.2021.121262
Teixeira, Santos, Fernandes, Costa-Rodrigues, Branco, Alendronic Acid as Ionic Liquid: New Perspective on Osteosarcoma, Pharmaceutics, doi:10.3390/pharmaceutics12030293
Teixeira, Santos, Ferraz, Prudêncio, Fernandes et al., A Novel Approach for Bisphosphonates: Ionic Liquids and Organic Salts from Zoledronic Acid, ChemMedChem, doi:10.1002/cmdc.201900397
Torchilin, Recent Advances with Liposomes as Pharmaceutical Carriers, Nat. Rev. Drug Discov, doi:10.1038/nrd1632
Uzunova, Filipova, Pavlova, Vekov, Insights into Antiviral Mechanisms of Remdesivir, Lopinavir/Ritonavir and Chloroquine/Hydroxychloroquine Affecting the New SARS-CoV-2, Biomed. Pharmacother, doi:10.1016/j.biopha.2020.110668
Vasconcelos, Sarmento, Costa, Solid Dispersions as Strategy to Improve Oral Bioavailability of Poor Water Soluble Drugs, Drug Discov. Today, doi:10.1016/j.drudis.2007.09.005
Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine Is a Potent Inhibitor of SARS Coronavirus Infection and Spread, Virol. J, doi:10.1186/1743-422X-2-69
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-NCoV) in Vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Wu, Zhao, Yu, Chen, Wang et al., A New Coronavirus Associated with Human Respiratory Disease in China, Nature, doi:10.1038/s41586-020-2008-3
Yao, Ye, Zhang, Cui, Huang et al., In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis, doi:10.1093/cid/ciaa237
Ziegler, Unanue, Decrease in Macrophage Antigen Catabolism Caused by Ammonia and Chloroquine Is Associated with Inhibition of Antigen Presentation to T Cells, Proc. Natl. Acad. Sci, doi:10.1073/pnas.79.1.175
{ 'indexed': {'date-parts': [[2024, 4, 8]], 'date-time': '2024-04-08T21:58:22Z', 'timestamp': 1712613502099}, 'reference-count': 72, 'publisher': 'MDPI AG', 'issue': '4', 'license': [ { 'start': { 'date-parts': [[2022, 4, 17]], 'date-time': '2022-04-17T00:00:00Z', 'timestamp': 1650153600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'funder': [ { 'DOI': '10.13039/501100001871', 'name': 'Fundação para a Ciência e Tecnologia', 'doi-asserted-by': 'publisher', 'award': [ 'UIDB/50006/2020', 'UIDP/50006/2020', 'Research 4 COVID-19 nº 582', 'PTDC/QUI-QOR/32406/2017', 'RECI/BBBBQB/0230/2012']}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:p>The development of effective antiviral drugs against SARS-CoV-2 is urgently needed ' 'and a global health priority. In light of the initial data regarding the repurposing of ' 'hydroxychloroquine (HCQ) to tackle this coronavirus, herein we present a quantitative ' 'synthesis and spectroscopic and thermal characterization of seven HCQ room temperature ionic ' 'liquids (HCQ-ILs) obtained by direct protonation of the base with two equivalents of organic ' 'sulfonic, sulfuric and carboxylic acids of different polarities. Two non-toxic and ' 'hydrophilic HCQ-ILs, in particular, [HCQH2][C1SO3]2 and [HCQH2][GlcCOO]2, decreased the ' 'virus-induced cytopathic effect by two-fold in comparison with the original drug, ' '[HCQH2][SO4]. Despite there being no significant differences in viral RNA production between ' 'the three compounds, progeny virus production was significantly affected (p &lt; 0.05) by ' '[HCQH2][GlcCOO]2. Overall, the data suggest that the in vitro antiviral activities of the ' 'HCQ-ILs are most likely the result of specific intra- and intermolecular interactions and not ' 'so much related with their hydrophilic or lipophilic character. This work paves the way for ' 'the development of future novel ionic formulations of hydroxychloroquine with enhanced ' 'physicochemical properties.</jats:p>', 'DOI': '10.3390/pharmaceutics14040877', 'type': 'journal-article', 'created': {'date-parts': [[2022, 4, 19]], 'date-time': '2022-04-19T06:39:31Z', 'timestamp': 1650350371000}, 'page': '877', 'source': 'Crossref', 'is-referenced-by-count': 5, 'title': 'Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2', 'prefix': '10.3390', 'volume': '14', 'author': [ {'given': 'Francisco', 'family': 'Faísca', 'sequence': 'first', 'affiliation': []}, {'given': 'Vanessa', 'family': 'Correia', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-8104-7008', 'authenticated-orcid': False, 'given': 'Željko', 'family': 'Petrovski', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-2520-1151', 'authenticated-orcid': False, 'given': 'Luís C.', 'family': 'Branco', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-0138-0944', 'authenticated-orcid': False, 'given': 'Helena', 'family': 'Rebelo-de-Andrade', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-8973-1595', 'authenticated-orcid': False, 'given': 'Miguel M.', 'family': 'Santos', 'sequence': 'additional', 'affiliation': []}], 'member': '1968', 'published-online': {'date-parts': [[2022, 4, 17]]}, 'reference': [ { 'key': 'ref1', 'unstructured': 'WHO Coronavirus (COVID-19) Dashboardhttps://covid19.who.int/'}, {'key': 'ref2', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fpsyg.2021.700815'}, {'key': 'ref3', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/CMR.00109-21'}, {'key': 'ref4'}, { 'key': 'ref5', 'unstructured': 'COVID-19 ' 'Treatmentshttps://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-treatments'}, {'key': 'ref6', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2007764'}, { 'key': 'ref7', 'doi-asserted-by': 'crossref', 'first-page': '497', 'DOI': '10.1056/NEJMoa2023184', 'article-title': 'Repurposed Antiviral Drugs for COVID-19—Interim WHO Solidarity Trial ' 'Results', 'volume': '384', 'author': 'Pan', 'year': '2021', 'journal-title': 'N. Engl. J. Med.'}, {'key': 'ref8', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2213-2600(22)00011-X'}, {'key': 'ref9', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.ppat.1009225'}, {'key': 'ref10', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41422-020-0282-0'}, {'key': 'ref11', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41421-020-0156-0'}, {'key': 'ref12', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa237'}, {'key': 'ref13', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/annrheumdis-2019-216655'}, {'key': 'ref14', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/annrheumdis-2019-215089'}, {'key': 'ref15', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/annrheumdis-2018-213512'}, {'key': 'ref16', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/rheumatology/kex286'}, {'key': 'ref17', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s12016-010-8243-x'}, {'key': 'ref18', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/1743-422X-3-39'}, {'key': 'ref19', 'doi-asserted-by': 'publisher', 'DOI': '10.1099/0022-1317-64-5-1149'}, {'key': 'ref20', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/j.1468-1293.2005.00259.x'}, {'key': 'ref21', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.bbrc.2004.08.085'}, {'key': 'ref22', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/1743-422X-2-69'}, {'key': 'ref23', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.01509-08'}, {'key': 'ref24', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/nrmicro3138'}, {'key': 'ref25', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/415686a'}, {'key': 'ref26', 'doi-asserted-by': 'publisher', 'DOI': '10.1073/pnas.75.7.3327'}, {'key': 'ref27', 'doi-asserted-by': 'publisher', 'DOI': '10.1073/pnas.79.1.175'}, {'key': 'ref28', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-020-2008-3'}, {'key': 'ref29', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)30251-8'}, {'key': 'ref30', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2020.02.052'}, {'key': 'ref31', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.biopha.2020.110668'}, {'key': 'ref32', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/14656566.2021.1898589'}, {'key': 'ref33', 'doi-asserted-by': 'publisher', 'DOI': '10.3399/bjgpopen20X101069'}, {'key': 'ref34', 'doi-asserted-by': 'publisher', 'DOI': '10.7573/dic.2020-4-5'}, {'key': 'ref35', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa623'}, {'key': 'ref36', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jps.22205'}, {'key': 'ref37', 'doi-asserted-by': 'publisher', 'DOI': '10.1124/pr.110.003459'}, {'key': 'ref38', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/ja048114o'}, {'key': 'ref39', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/cg8009496'}, {'key': 'ref40', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijpharm.2012.11.028'}, {'key': 'ref41', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0939-6411(00)00076-X'}, {'key': 'ref42', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.drudis.2007.09.005'}, {'key': 'ref43', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/nrd1632'}, {'key': 'ref44', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.addr.2007.05.010'}, {'key': 'ref45', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/ijms21218298'}, {'key': 'ref46', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.molliq.2021.115988'}, {'key': 'ref47', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/pharmaceutics12111078'}, {'key': 'ref48', 'doi-asserted-by': 'publisher', 'DOI': '10.1039/b706677p'}, {'key': 'ref49', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/acs.chemrev.6b00562'}, {'key': 'ref50', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/j.1747-0285.2011.01114.x'}, {'key': 'ref51', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijpharm.2014.04.034'}, {'key': 'ref52', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/pharmaceutics12080694'}, {'key': 'ref53', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/iecp2020-08649'}, {'key': 'ref54', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/pharmaceutics12030221'}, {'key': 'ref55', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/pharmaceutics12100952'}, {'key': 'ref56', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/cmdc.201900397'}, {'key': 'ref57', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/pharmaceutics12030293'}, {'key': 'ref58', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijpharm.2021.121262'}, {'key': 'ref59', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/cmdc.201900040'}, {'key': 'ref60', 'doi-asserted-by': 'publisher', 'DOI': '10.1039/C7NJ01398A'}, {'key': 'ref61', 'doi-asserted-by': 'publisher', 'DOI': '10.1039/C3RA44286A'}, {'key': 'ref62', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s11914-020-00612-4'}, {'key': 'ref63', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fchem.2018.00612'}, {'key': 'ref64', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/acs.chemmater.6b01247'}, {'key': 'ref65', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s10973-019-08951-w'}, {'key': 'ref66', 'doi-asserted-by': 'publisher', 'DOI': '10.1039/C4RA09906K'}, { 'key': 'ref67', 'first-page': '6-1-6', 'article-title': '1-Octanol/Water Partition Coefficients of Dialkylated Methylimidazolium ' 'Halide Salts', 'volume': '15', 'author': 'Gard', 'year': '2015', 'journal-title': 'Glob. J. Sci. Front. Res. B Chem.'}, { 'key': 'ref68', 'series-title': 'Laboratory Biosafety Guidance Related to Coronavirus Disease (COVID-19): ' 'Interim Guidance, 28 January 2021', 'year': '2021'}, { 'key': 'ref69', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/oxfordjournals.aje.a118408'}, {'key': 'ref70', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cmi.2020.10.003'}, {'key': 'ref71', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s11743-006-1000-8'}, { 'key': 'ref72', 'series-title': 'Molecular Interactions', 'author': 'Ratajczak', 'year': '1980'}], 'container-title': 'Pharmaceutics', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.mdpi.com/1999-4923/14/4/877/pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 4, 19]], 'date-time': '2022-04-19T06:53:02Z', 'timestamp': 1650351182000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.mdpi.com/1999-4923/14/4/877'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 4, 17]]}, 'references-count': 72, 'journal-issue': {'issue': '4', 'published-online': {'date-parts': [[2022, 4]]}}, 'alternative-id': ['pharmaceutics14040877'], 'URL': 'http://dx.doi.org/10.3390/pharmaceutics14040877', 'relation': {}, 'ISSN': ['1999-4923'], 'subject': [], 'container-title-short': 'Pharmaceutics', 'published': {'date-parts': [[2022, 4, 17]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit